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As a calcium sensitizer and inodilator that augments cardiac contractility without in-
creasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may
be well configured to deliver inotropic support in cases of acute heart failure (AHF).
Other factors favouring levosimendan in this setting include its extended duration of
action due to the formation of an active metabolite and the lack of any attenuation
of effect in patients treated with beta-blockers. Effects of levosimendan on systemic
haemodynamics include its significant, dose-dependent increases in cardiac output,
stroke volume and heart rate, and decreases in right and left ventricular filling and
total peripheral resistance. Rapid and sustained reduction in levels of natriuretic
peptides is a consistent effect of levosimendan use and potentially favourable
effects on other neurohormonal indicators of cardiac distress are also observed.
Levosimendan has repeatedly been shown to be effective in relief of symptoms of
AHF, notably dyspnoea and fatigue, while mortality data from clinical trials and reg-
istries suggest that levosimendan is markedly less likely than catecholaminergic ino-
tropes to worsen prognosis. The vasodilator pharmacology of levosimendan is also
pertinent to the drug’s use in AHF, in which setting organ under-perfusion is often a
key pathology. These considerations suggest that levosimendan may have a more
favourable impact on the circumstances of the majority of AHF patients than adre-
nergic agents that act only or primarily as cardiac stimulants. They also suggest that
levosimendan may advantageously be integrated into a comprehensive strategy of
early intervention designed and intended to prevent cardiac destabilization worsen-
ing to the point where hospitalization is necessary. Levosimendan should be used
with caution and with tightened haemodynamic monitoring in patients who have low
baseline blood pressure (systolic blood pressure <100mmHg; diastolic blood pressure
<60mmHg), or who are at risk of a hypotensive episode.
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Introduction
Acute heart failure (AHF) is characterized in the 2016
European Society of Cardiology (ESC) guidelines for the di-
agnosis and treatment of acute and chronic heart failure
(HF)1 as ‘rapid onset or worsening of symptoms and/or
signs of HF. It is a life-threatening medical condition requir-
ing urgent evaluation and treatment, typically leading to
urgent hospital admission’.
The ESC guidelines acknowledge immediately that this
umbrella definition of AHF encompasses a condition with
an extensive array of possible causes: while AHF may be a
de novo clinical incident, it is more often a consequence of
acute decompensation of chronic HF. Similarly, it may origi-
nate from primary cardiac dysfunction (most usually acute
myocardial dysfunction, which itself may arise from a
range of causes, as well as acute valve insufficiency) or it
may, especially in patients with chronic HF, be initiated by
the operation of external precipitating factors. An exten-
sive range of such factors is identified in the 2016 ESC
guidelines.1
Identification (or exclusion) and correction of all such
precipitants is an urgent priority in the first-phase response
to a presentation of presumed or suspected AHF. In this
context, it should be noted that AHF precipitated by
either an episode of acute coronary syndrome (ACS) or an
infection is attended by exceptionally high short-term
mortality.2 When ACS is attended by cardiogenic shock a
validated risk prediction instrument such as the CardShock
risk score may be used to aid clinical decisionmaking.3
Clinical classification, as endorsed by the ESC guidelines,
emphasizes the significance of congestion (pulmonary, jug-
ular, peripheral or paroxysmal nocturnal dyspnoea, ascites,
intestinal congestion, and hepatic congestion of the
hepato-jugular reflex) and hypoperfusion, indicated by oli-
guria, dizziness, mental confusion and cold, sweated ex-
tremities. (It should be emphasized that hypoperfusion is
not a synonym for hypotension, although these conditions
coexist in the majority of cases.) After the urgent and im-
mediate phases of stabilization and a diagnostic work-up
including natriuretic peptide determinations (primarily as
an aid to excluding AHF), this wet/cold/dry/warm classifi-
cation can be used to profile patients and outline their
therapeutic trajectory (Figure 1). This stratification identi-
fies the ‘wet and cold’ patient as the type most likely to be
a candidate for inotropic therapy, as one of a range of ther-
apeutic interventions.
These extracts from expert guidance provide a frame-
work within which to assess the potential contribution of
levosimendan to themanagement of AHF.
As a cardiac myofilament calcium sensitizer, levosimen-
dan increases cardiac contractility by increasing calcium
sensitivity rather than by increasing intracellular ionic
free calcium.4 Consequently, it is not associated with
Figure 1 European Society of Cardiology-advised criteria for classifying acute heart failure based on the presence/absence of congestion and/or hypo-
perfusion. From Ponikowski et al.1
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increases in myocardial oxygen demand5,6 or ischaemia.7,8
Levosimendan is further distinguished by its pharmacoki-
netics, in particular the formation via a reduction–
acetylation pathway in the intestines of a long-acting ac-
tivemetabolite designated OR-1896. This compound shares
the pharmacologic and haemodynamic properties of the
parent drug while having a greatly extended plasma half-
life.9 The particular kinetics of this metabolite contribute
to the persistence of therapeutic effects after a single infu-
sion of the parent drug.
More than 3000 patients have been involved in primary
and regulatory clinical trials of levosimendan in left sided
HF. Narrative summaries of key studies appear in Table 1.
Consolidated findings from these studies are discussed
below.
Haemodynamic effects
Levosimendan produces significant, dose-dependent
increases in cardiac output (CO) and stroke volume, and
decreases in pulmonary capillary wedge pressure (PCWP),
mean blood pressure (BP), mean pulmonary artery pressure
(PAP), mean right atrial pressure, and total peripheral re-
sistance.10 These effects are registered rapidly (within a
few minutes of starting infusion). There is no evidence of
the development of tolerance or attenuation of effect
even after infusions up to 48h in duration.11 The presence
of the long-acting metabolite designated OR-1896 means
that these core haemodynamic effects persist for several
days after termination of levosimendan infusion and for
much longer thanwith dobutamine.9
The increase in CO evoked by levosimendan is similar to
that achieved with dobutamine at comparable doses but
the reduction in PCWP produced by levosimendan is consid-
erably greater. Moreover, and in contrast to dobutamine,
the haemodynamic effects of levosimendan are not attenu-
ated by concomitant beta-blocker use. This difference con-
tributes to the position of the 2016 ESC HF guidelines that
levosimendan should be the preferred agent when inotropy
is indicated for an HF patient pretreated with a beta-
blocker.1
Use of an initial bolus of levosimendan is nowadays gen-
erally avoided in order to minimize the risk of hypotension.
Infusion is most often commenced initially at a dose of
0.1mg/kg/min [or 0.05mg/kg/min when systolic blood
pressure (SBP) is marginal] and titrated to 0.2mg/kg/min if
BP remains stable after the first 2–3 h. The recommended
duration of infusion in AHF is 24h.
Levosimendan should be used with caution—and with no
bolus dose—in patients with low baseline SBP (<100mmHg)
or diastolic blood pressure (DBP, <60mmHg), or those at
risk of a hypotensive episode. Patients who might be con-
sidered ineligible for levosimendan therapy on these
grounds account for <10% of the AHF population according
to the 2016 ESC guidelines.1 Hypovolaemia should be cor-
rected prior to levosimendan infusion, as a precautionary
measure.
Effects on neurohormones
Rapid and sustained reduction in levels of natriuretic pepti-
des is a hallmark of levosimendan use in clinical trials. The
data depicted in Figure 2, from the REVIVE II study,12 may
be regarded as exemplary of findings in other studies.
Correlations between discharge brain natriuretic pep-
tide (BNP) and longer-term clinical prognosis are not al-
ways resilient or persistent,13,14 and it would be imprudent
Table 1 Narrative summaries of principal controlled trials of levosimendan in left-sided acute heart failure
In the LIDO study, levosimendan was compared with dobutamine in 203 patients with low-output heart failure who required right
heart catheterization and treatment with an intravenous inotropic drug. Levosimendan was administered as a 24-h intravenous
infusion at a rate of 0.1–0.2 mg/kg/min.16
The RUSSLAN study (N¼ 504) was primarily a safety evaluation of levosimendan in patients with left ventricular failure complicat-
ing an acute myocardial infarction.17 Patients randomized to levosimendan were treated with a 6-h intravenous infusion at a rate
of 0.1–0.4 mg/kg/min. Invasive haemodynamics were not performed.
The SURVIVE study (N¼ 1327) compared the effects of levosimendan or dobutamine on mortality in patients with severe systolic
heart failure. Levosimendan was infused at rates of 0.1–0.2mg/kg/min for 24 h.18
The REVIVE studies (REVIVE I, n¼ 100; REVIVE II, n¼ 600) evaluated the efficacy of levosimendan on symptoms of acute heart fail-
ure based on a novel composite endpoint of clinically relevant measures expressed as ‘improved’, ‘unchanged’, or ‘worse’ during
5 days of observation. Levosimendan was administered as a 24-h intravenous infusion at a rate of 0.1–0.2 mg/kg/min. Both REVIVE
studies were conducted mainly in the USA.12
Figure 2 Levosimendan infusion in the REVIVE II study was associated
with a marked and sustained reduction in circulating brain natriuretic
peptide levels. From Packer et al.12
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to assume from its effect on BNP alone that levosimendan
is certain to have an enduring impact on prognosis in all
cases.
Impact on signs and symptoms of acute heart
failure
In patients with clear signs of pulmonary oedema and ele-
vated PCWP who do not respond adequately to vasodila-
tors, selected inotropes are acknowledged for their ability
to reduce left ventricular filling pressures and decongest
the lungs. Within the broad class of inotropes, the reduc-
tions in PCWP and right atrial pressure produced by levosi-
mendan are greater than those for agents such as
dobutamine.15
Factors necessitating the use of rescue medications in
the REVIVE programme are summarized in Table 2 and
show consistent advantages with levosimendan, including
in the major categories of ‘worsening dyspnoea or tachyp-
noea’ and ‘persistent/unresponsive symptoms’.12 It should
be noted that many patients in both REVIVE studies were in
receipt of extensive and aggressive polypharmacy before
the introduction of levosimendan and most patients who
received levosimendan were infused at the maximum per-
mitted rate of 0.2mg/kg/min.
Dyspnoea and fatigue symptoms also responded better
to levosimendan than to control therapies in the LIDO trial
but, in that instance, the treatment effect of levosimendan
was numerically larger but not statistically significant (dys-
pnoea improvement 68% vs. 59%, P¼ 0.865; fatigue im-
provement 63% vs. 47%, P¼ 0.155).16
Clinical outcomes
Hospitalization data
Length of hospital stay and time alive and out of hospital
offer a perspective on the effectiveness of therapy in AHF.
Patients in the levosimendan group of the LIDO study spent
significantly more days alive and out of hospital than
dobutamine-treated patients in a retrospective 180-day
follow-up analysis (median 157 vs. 133 days; P¼ 0.027).16
In RUSSLAN, the combined risk of death and worsening HF
was significantly lower in patients treated with levosimen-
dan than in the control group during the infusion period (2%
vs. 6%; P¼ 0.033) and at 24h (4% vs. 9%; P¼ 0.044)17 while,
in the REVIVE II study, a greater percentage of patients
treated with levosimendan were released within 5 days
(46% vs. 37%) and the mean duration of the initial hospitali-
zation was almost 2 days shorter in the levosimendan group
than the placebo group (7.0 vs. 8.9 days).12 In SURVIVE, the
mean number of days alive and out of hospital during
189days of follow-up was 120.2 in the levosimendan group
vs. 116.6 in the dobutamine group (P¼ 0.3).18
Mortality data
Thirty-one-day mortality was examined as a secondary
endpoint in LIDO and revealed a survival advantage from
levosimendan treatment [mortality rate 8% vs. 17% with
dobutamine, hazard ratio (HR) 0.43, P¼ 0.049].16 This ini-
tial gain was corroborated in a retrospective extension of
follow-up to 180days (mortality rate 26% vs. 38% with
dobutamine, HR 0.57, P¼ 0.029). Similar findings emerged
from the RUSSLAN study, in which a survival benefit from
levosimendan persisted in a retrospective follow-up to
180days (23% vs. 31%; P¼ 0.053).17
In the SURVIVE and REVIVE studies, in contrast, there
was no significant difference in survival between the study
groups.12,18
Evidence from the ALARM-HF registry suggests that the
mixed inodilator profile of levosimendanmay be associated
in routine clinical practice with a mortality rate much
closer to that associated with vasodilators than those
seen with calcium-mobilizing inotropes (Figure 3).19
Complementary data on this theme have recently emerged
from the ESC Heart Failure Long-Term Registry, which
revealed that 12% of patients undergoing unscheduled
hospitalizations for AHF received intravenous (i.v.) ino-
tropes and/or vasopressors.20
A survival effect of levosimendan approximating to a 5%
absolute risk reduction has been documented by Landoni
et al. in a meta-analysis of 45 randomized controlled stud-
ies that published mortality data involving 5480 patients
(levosimendan n¼ 2915; control n¼ 2565).21 There was
Table 2 Summary of worsening clinical status leading to use of rescue therapy in the REVIVE programme









Proportion requiring rescue therapy 16% 29% 15% 26%
Worsening dyspnoea or tachypnoea 10% 12% 7% 13%
Increased pulmonary oedema 0% 2% 3% 6%
Diaphoresis 0% 2% 1% 1%
Cool extremities and cyanosis 2% 2% 0% 2%
Worsening renal function 6% 2% 3% 5%
Decreased mental status 0% 0% 1% 2%
Persistent/unresponsive symptoms 10% 18% 6% 11%
From Packer et al.12
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statistically robust evidence of a survival advantage of lev-
osimendan vs. either dobutamine (odds ratio 0.68;
P¼ 0.003) or placebo (odds ratio 0.82; P¼ 0.02) and consis-
tency of effect was observed across an extensive range of
sub-analyses. There was also evidence of reduced length of
hospital stay [weighted mean difference (WMD) 1.31;
P¼ 0.007].
Subgroup analyses from REVIVE and SURVIVE data
Subgroup analysis of these two large trials of levosimen-
dan12,18 produced a range of interesting insights.
SURVIVE
Although no significant difference was demonstrated be-
tween levosimendan and placebo for the primary endpoint
of 180-daymortality, the survival rate in the levosimendan-
treated patients was significantly higher in the subgroup of
patients with a history of HF (1171 patients, 88.2% of the
study population), with a net benefit of 19 fewer deaths up
to 31days (P¼ 0.05). Separately, randomization to levosi-
mendan was associated with significantly lower early-
phase (Days 0–5) mortality in the subgroup of patients ex-
posed to concomitant beta-blocker therapy (P¼ 0.03).22 It
is of note that only half of patients in the SURVIVE trial
were in receipt of beta-blockers before the introduction of
study medication, a much lower percentage than is en-
countered in many current randomized clinical trials, in
which the usage rate for beta-blockers is often 90%.
Prima facie, therefore, clinical circumstances favouring
the use of levosimendan may be more prevalent now than
when SURVIVE was conducted.
REVIVE
Post hoc analyses of the REVIVE II dataset identified base-
line SBP <100mmHg or DBP <60mmHg at baseline as fac-
tors associated with increased mortality risk and revealed
that, in patients with initial low BP, mortality was 27% for
levosimendan vs. 16% for placebo. Of note, the excess mor-
tality in the whole levosimendan cohort occurred during
the index admission (15 deaths vs. 6); deaths during follow-
upwere identical in both groups (n¼ 29).
Re-analysis of the mortality data excluding patients with
low baseline arterial BP eliminated the early excess of mor-
tality in the levosimendan cohort (three deaths vs. five
with placebo); deaths during follow-up remained very simi-
lar (levosimendan, n¼ 13; placebo, n¼ 12) so that overall
mortality in patients with well-supported BP at baseline
was similar between groups (HR 0.92, P¼ 0.81; Figure 4).
The study’s composite primary endpoint, which was posi-
tive for levosimendan in the overall study population, was
likewise positive in the subset of patients with higher base-
line BP.
These analyses identified low BP at baseline as a possible
risk factor for the use of levosimendan and the current
summary of product characteristics reflects that verdict.
Safety synopsis
An integrated safety data summary prepared by the spon-
sor of the placebo-controlled studies of i.v. levosimendan
in AHF revealed no difference in the proportion of patients
experiencing reduction in arterial BP in response to treat-
ment (23.1% vs. 23.1%). REVIVE II (N¼ 600), as noted
above, was an outlier to this aggregate trend, with 52.6%
of levosimendan-treated patients experiencing a reduction
in BP, compared with 37.9% in the placebo group
(P< 0.001).
The integrated summary also identified a greater likeli-
hood of atrial arrhythmias with levosimendan than placebo
(8.2% vs. 5.4%; P¼ 0.024). This difference was slightly
more marked than the average in the REVIVE II study (9%
vs. 2%; P< 0.001), which also recorded a statistically signif-
icant difference in the incidences of ventricular tachycar-
dia (levosimendan 25%, placebo 17%, P¼ 0.031). However,
that difference was not replicated in the integrated sum-
mary (levosimendan 10.0%, placebo 11.3%, P¼ 0.371).
Figure 4 Analysis of deaths in the REVIVE II study according to patients’
baseline blood pressure revealed an association between higher blood
pressures and improved outcomes with levosimendan use. From Packer
et al.12Figure 3 Levosimendan, a calcium-sensitizing inotrope and vasodilator,
was associated with a substantially lower mortality rate in the population
of the ALARM-HF registry than was seen with traditional adrenergic, cal-
cium-mobilizing inotropes such as dobutamine. From Mebazaa et al.19
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The incidences of worsening HF and renal function dis-
turbances, recorded as adverse events, were significantly
lower in the levosimendan group than the placebo group
(HF events, 15.6% vs. 28.4%, P< 0.001; renal events, 6.9%
vs. 10.4%, P¼ 0.007).
There was no statistically significant difference between
the levosimendan and placebo groups in respect of cardiac
ischaemia (7.3% vs. 8.9%, P¼ 0.233); decreased haemoglo-
bin (2.3% vs. 3.8%, P¼ 0.058); decreased potassium (4.9%
vs. 7.0%, P¼ 0.059); or increased blood glucose (1.6% vs.
2.6%, P¼ 0.117). It should be noted in this context that,
while the numerical differences in this analysis favour levo-
simendan, reductions in serum potassium and haemoglobin
were reported in early small-scale studies of i.v. levosimen-
dan, and that correction of hypokalaemia is recommended
before administering levosimendan.
The safety of levosimendan in AHF has also been the sub-
ject of a meta-analysis by Gong et al.23 From 5349 patients
in 25 randomized controlled studies including LIDO,
SURVIVE, and the REVIVE programme, but excluding
RUSSLAN, these investigators concluded that levosimendan
therapy increased the risk of recurrence of extrasystoles
[risk ratio (RR) 1.88, 95% confidence interval (CI) 1.26–
2.81, P¼ 0.002], headache or migraine (RR 1.94, 95% CI
1.54–2.43; P< 0.00001) and hypotension (RR 1.33, 95% CI
1.15–1.53; P¼ 0.0001) in patients with HF, compared with
combined control therapy comprising placebo or dobut-
amine. There were non-statistically significant differences
in the RRs, several of which favoured levosimendan, for
ventricular tachycardia, constipation, diarrhoea, hypoka-
laemia, nausea, vomiting, urinary tract infection, dizziness
and angina pectoris, chest pain, or myocardial ischaemia.
Effects on BP were recorded in this meta-analysis as effi-
cacy variables. Compared with dobutamine, levosimendan
was associated with reductions in SBP (WMD 7.08mmHg,
P¼ 0.02), DBP (WMD4.75mmHg, P< 0.00001), andmean
arterial pressure (WMD 0.25mmHg, P¼ 0.02), whereas
stroke volume was enhanced (WMD þ9.02, P¼ 0.02).
Levosimendan also lowered SBP significantly more than
placebo (WMD4.76mmHg, P¼ 0.003).
Levosimendan in acute heart failure
complicating acute coronary syndrome
The incidence of AHF as a complication of ACS has de-
creased over recent years, but it is still a significant com-
plication of ACS, affecting a substantial proportion of
patients and being associated with worse outcomes.24
RUSSLAN17 is the largest placebo-controlled study of lev-
osimendan in this scenario, and was primarily a safety
study, but decreased incidence of worsening HF and
improvements in short- and long-term mortality were
noted. Corroboration of that effect was not forthcoming
from the dobutamine-controlled SURVIVE study,18 in which
178 patients (13% of the study cohort) were classified as
having acute myocardial infarction (AMI), but it is of note
that, in that subset of patients, 31-day mortality was 4%
lower in the levosimendan arm than with dobutamine [23/
83 (28%) vs. 30/95 (32%), RR 0.83 (95% CI 0.48–1.43)],
whereas in the non-AMI contingent (n¼ 1149), death rates
at 31days were very similar in both treatment assignments
[56/581 (10%) vs. 61/568 (11%), RR 0.89 (95% CI 0.62–
1.28)].
A series of smaller studies have added to the database of
experience with levosimendan in this setting.25–31
Individually, these studies do not provide adequately pow-
ered insights into any effect of levosimendan on survival in
this situation but they have produced repeated indications
of favourable effects on systemic haemodynamics and on
left ventricular function and wall motion. In conjunction
with the latter, several reports have documented acceler-
ated recovery from Takotsubo cardiomyopathy (transient
left ventricular apical ballooning syndrome) with levosi-
mendan, accompanied by favourable haemodynamic
responses and more rapid restoration of pre-incident tro-
ponin levels.32,33
Expert opinion on the use of levosimendan in AHF com-
plicating ACS/AMI currently advises that it may be consid-
ered as an alternative to adrenergic agents in all patients
who have received chronic beta-blocker therapy or in those
whose urinary output is insufficient after diuretics. It may
also be relevant to the needs of patients whose SBP is in
the range 85–100mmHg (equivalent to Killip Class III, with
acute pulmonary oedema) and may be a preferred inter-
vention (in combination with noradrenaline or other vaso-
pressors) in patients with cardiogenic shock
(approximating to Killip Class IV and SBP <85mmHg, with
indications of peripheral vasoconstriction34).
Renal effects of levosimendan
The emphasis on preservation of renal function in clinical
management protocols reflects appreciation of the rela-
tion between worsening kidney function and deterioration
of prognosis in AHF.
Haemodynamics are not the sole contributors to end-
organ damage, but an increase in CO and a reduction in
central venous pressure (CVP) are nonetheless important
therapeutic targets for the preservation or recovery of re-
nal function. Levosimendan has been actively evaluated
for its effects on renal function in HF. The balance of the
evidence, as summarized in a recent review,35 suggests a
modest but sustained advantageous effect mediated pri-
marily through changes in CO and CVP. Separately, direct
observation of human renal arteries after administration of
levosimendan has documented renal arterial vasodilatation
and augmented renal blood flow with increase in glomeru-
lar filtration rate (GFR) and promotion of diuresis without
compromise of renal oxygenation,36 and theoretically ad-
vantageous effects on various markers of kidney function
have been reported in levosimendan-treated patients with
acutely decompensated AHF and renal impairment.37
Further recent insights into renal effects of levosimen-
dan have been reported by Lannemyr et al.38 As part of an
elective cardiac work-up, 32 adult patients with chronic HF
(mean baseline left ventricular ejection fraction 27%) and
impaired renal function (mean GFR <80mL/min/1.73 m2)
were randomly assigned to short-term (75min) treatments
with either levosimendan (loading dose of 12mg/kg over
10min, then infusion at 0.1mg/kg/min for 65min; n¼ 16)







ulib user on 08 February 2019
or dobutamine (continuous infusion started at 5.0mg/kg/
min for 10min, then 7.5mg/kg/min for 65min; n¼ 16).
Both treatments were associated with quantitatively
and qualitatively very similar alterations in major systemic
haemodynamic indices and significant (P< 0.05) enhance-
ment of renal blood flow but only levosimendan therapy
was associated with a significant increase in GFR (P< 0.05
vs. baseline).
In aggregate, these observations are compatible with a
scenario in which enhancement of CO by levosimendan ini-
tiates a virtuous circle in which improved GFR and diuresis
lead to decongestion and a lower CVP, which in turn pro-
motes further improvement in both cardiac and renal func-
tion. In addition to these clinical findings, experimental
observations suggest that, in some situations, levosimen-
dan may exert renal-protective qualities arising from anti-
oxidant, anti-apoptotic, and cytoprotective actions.39
Zangrillo et al.40 have recently published the findings of
a subgroup analysis of the CHEETAH study linking levosi-
mendan with a lower rate of post-operative acute kidney
injury vis-à-vis placebo (30% vs. 52%, P¼ 0.035) in patients
undergoing mitral valve surgery who developed post-
operative myocardial dysfunction/low CO syndrome.
These findings are consistent with other meta-analyses
that have suggested a renal-protective benefit of levosi-
mendan in a range of clinical situations41,42 but, particu-
larly because the REVIVE programme—to date the largest
randomized study of levosimendan in AHF—produced no
indications of significant impact on renal function,12 such
post hoc exercises must be regarded as in need of valida-
tion in prospective, randomized, controlled trials.
These reservations notwithstanding, however, it is rea-
sonable to conclude that inotropes or inodilatorsmay be in-
dicated for short-term management in AHF with renal
dysfunction—mostly in cases of low-output HF that can pro-
voke renal hypoperfusion—and to assert that levosimendan
is probably currently underutilized in clinical practice, es-
pecially in ‘wet’ patients (Figure 1) who do not respond to
diuretics.
Right heart failure and pulmonary
hypertension
Decisive randomized trials of levosimendan are lacking
in right ventricular failure with or without pulmonary hy-
pertension (PH) but two proof-of-concept trials by Jiang et
al.43 and of Kleber et al.44 suggest some benefits.
The first of these studies was an open-label uncontrolled
trial in 45 hospitalized patients with precapillary PH and
right HF.43 Levosimendan was administered at a rate of
0.05–0.1mg/kg/min, up to a total dose of 12.5mg.
On Day 7 after levosimendan infusion, 7 of 13 patients
initially in World Health Organization functional Class IV
had improved their functional status by at least one class
(P¼ 0.008). The second of the primary endpoints, Borg dys-
pnoea score, was also significantly improved (P< 0.001),
as were the secondary outcomes of 6-min walk test dis-
tance and N-terminal pro-BNP (P< 0.001 for both).
Diastolic blood pressure decreased significantly in re-
sponse to levosimendan infusion (68.46 11.6 vs.
63.76 10.7mmHg, P¼ 0.01) but only one patient required
dopamine as a precaution against hypotension.
Kleber et al.44 evaluated levosimendan in a placebo-
controlled trial of 28 patients with PH (n¼ 8), pulmonary
venous hypertension resulting from left ventricular failure
(n¼ 17) or chronic thrombo-embolic PH (n¼ 3). Patients
were randomized in a 1:2 ratio to placebo or levosimendan,
which was initiated at a loading dose of 12mg/kg (infused
over 10min) followed by a continuous infusion of 0.1mg/
kg/min for 50min. The infusion rate was thereafter dou-
bled and maintained for 23h if the initial dose was well tol-
erated. Levosimendan was then re-administered at 2-week
intervals as a continuous infusion (0.2mg/kg/min for 6 h)
for a total of five cycles of treatment.
A total of 24 of the 28 randomized patients (levosimen-
dan, n¼ 16; placebo, n¼ 8) completed the study as
planned. One levosimendan and two placebo patients dis-
continued due to an adverse event (hypotension in the lev-
osimendan patient) and one levosimendan patient
withdrew consent.
Levosimendan reduced pulmonary vascular resistance
(PVR) following the initial 24-h infusion by 126 9% (vs. an
increase of 256 11% in the placebo group, P¼ 0.009).
Pulmonary vascular resistance at 8weeks remained lower
in patients treated with levosimendan but the differences,
while substantial, were not statistically significant (levosi-
mendan –216 83%, n¼ 13; placebo, þ356 73%, n¼ 7;
P¼ 0.253).
A Phase II double-blind, randomized, placebo-controlled
study of levosimendan in pulmonary hypertension in
patients with heart failure with preserved left ventricular
ejection fraction (PH-HFpEF) is ongoing in the USA
(NCT03541603).
Conclusions
The applications of levosimendan in the management of
AHFmay be summarized as follows.
• All cases of AHF in patients who are on beta-blockers.
• In cardiogenic shock: to improve cardiac function and
reduce catecholamine requirements.
• In ACS: for its cardioprotective qualities, to limit myo-
cyte loss and improve heart function.
• In cardio-renal syndrome: to relieve renal congestion
and improve kidney function.
• In right HF: to improve right heart function, reduce
venous congestion, reduce PAP, and improve kidney
function.
Levosimendan should be considered more often as a
preferable alternative to conventional adrenergic ino-
tropes. We base this conclusion on assessment of the drug’s
haemodynamic effects and its highly reassuring safety pro-
file in clinically unstable patients. The question of mortal-
ity/survival benefit remains contentious but the striking
lack of any increase in mortality with levosimendan in the
ALARM-HF registry (Figure 3), along with direct comparison
with dobutamine in randomized clinical trials and in meta-
analysis,21 persuades us that, among available inotropes,
levosimendan is least likely to worsen prognosis. Given the







ulib user on 08 February 2019
scale of the mortality effect recorded with other agents in
the ALARM-HF dataset this is a potentially major gain, sep-
arate from any wider consideration of the ancillary fea-
tures and benefits of levosimendan. It may also be argued
that levosimendan (along with numerous other drugs)
has suffered from shifting expectations in this area.
The SURVIVE investigators noted that, in AHF, ‘there is
a need for agents that at least improve haemodynamics
and relieve symptoms without adversely affecting
survival’.18 Levosimendan has consistently met that stan-
dard for being a useful addition to the options for AHF
treatment.
The vasodilator pharmacology of levosimendan is perti-
nent to the drug’s use in low-output states such as AHF
(and also cardiogenic shock). To characterize such condi-
tions solely as ‘low-output states’ may be misleading
because, in many cases, a key pathology is organ hypoper-
fusion and a preoccupation with raising SBP at the expense
of restoring appropriate organ perfusion may be detrimen-
tal to some patients. The use of a drug such as levosimen-
dan that delivers both augmentation of CO plus
venodilatation may therefore be expected to have a more
favourable impact on the circumstances of some patients
than an agent that acts only as a cardiac stimulant or pres-
sor,45 while also identifying it as an option for patients who
are normally treated with vasodilators.
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